Healthpeak Properties (DOC) Earnings Date & Reports

Key Takeaways

• Healthpeak Properties (DOC) reported third quarter 2026 net income of $0.02 per share and Funds From Operations (FFO) as Adjusted of $0.44 per share.
• Total revenue reached $820.89 million, up 16.3% year over year and ahead of the roughly $758 million consensus estimate.
• FFO as Adjusted of $0.44 per share edged past the $0.43 consensus, while same-store net operating income (NOI) grew 3.6% year over year.
• The company raised its full-year 2026 FFO as Adjusted guidance, reflecting strength in its senior housing and lab segments.
• Majority-owned Janus Living posted revenue growth of 78% and Adjusted EBITDAre growth of 101% year over year.
• For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Interested in automated market insights? Discover Trending AI Robots to explore AI-driven trading ideas.

Earnings Context and Why It Matters

Healthpeak Properties is a real estate investment trust (REIT) and S&P 500 company focused on healthcare discovery and delivery, spanning outpatient medical buildings, life science labs, and senior housing. Its third quarter 2026 results arrive at a pivotal moment, as the company continues integrating its majority stake in Janus Living following that entity's initial public offering (IPO) earlier in 2026. Investors are watching closely because Healthpeak's diversified healthcare portfolio now blends stable outpatient medical cash flows with faster-growing senior housing and a recovering lab segment. The quarter's lease execution figures, same-store growth, and updated guidance offer a clear read on demand across each business line, making this release a key barometer for the healthcare real estate sector's trajectory.

Reported Results

For the quarter ended September 30, 2026, Healthpeak reported diluted net income of $0.02 per share, compared with a net loss of $0.17 per share in the prior-year period. Diluted FFO as Adjusted, a key profitability metric for REITs that excludes real estate depreciation and certain non-recurring items, came in at $0.44 per share, down modestly from $0.46 a year earlier but above the $0.43 consensus estimate. Total revenue of $820.89 million rose 16.3% year over year and surpassed the approximately $758 million consensus.

Same-store adjusted NOI grew 3.6% overall, led by a 25.9% increase in senior housing. Outpatient medical same-store NOI rose 3.1%, while the lab segment declined 0.7%. Notably, lab occupancy increased 130 basis points (bps) sequentially and 270 bps since year-end 2025, signaling gradual stabilization. Janus Living contributed revenue of $268 million, up 78% year over year, with Adjusted EBITDAre up 101%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking healthcare REITs like DOC or scanning broader sectors, the AI Screener offers a streamlined way to identify actionable setups.

Market Reaction and Investor Sentiment

Healthpeak shares have drawn mixed sentiment in recent weeks, with the stock down roughly 2.4% over the past month heading into the report, according to market data. The earnings release and increased full-year FFO guidance provide a constructive backdrop, particularly given the strength in senior housing and the sequential improvement in lab occupancy. However, investors remain attentive to the lower diluted earnings-per-share guidance, which reflects higher depreciation and amortization from Janus Living's senior housing acquisitions. The post-earnings conference call will likely shape near-term sentiment as management elaborates on leasing momentum and capital allocation priorities.

Forward Outlook and Key Factors to Monitor

Healthpeak raised its full-year 2026 diluted FFO as Adjusted guidance to a range of $1.76 to $1.78 per share, a $0.02 midpoint increase, while lifting its total same-store cash adjusted NOI growth outlook to 0.5% to 2.0%. At the same time, diluted earnings-per-share guidance moved lower to $0.39 to $0.41, reflecting depreciation and amortization tied to senior housing acquisitions.

Investors should monitor several catalysts in the coming quarters. First, lab leasing activity remains a central theme; the company executed 480,000 square feet of lab leases in the quarter and has an additional 643,000 square feet executed or under letter of intent. Continued occupancy gains could support same-store NOI recovery in that segment.

Second, Janus Living's acquisition pipeline is a key growth driver. The entity closed $1.75 billion of senior housing acquisitions during the quarter and roughly $370 million more through late October. How quickly these properties contribute to earnings and whether the favorable senior housing supply-demand backdrop persists will matter for consolidated results.

Finally, balance sheet and cost trends deserve attention. Net debt to Adjusted EBITDAre stood at 4.7x, and the company entered a new $500 million delayed-draw term loan facility, leaving it with $3.8 billion of liquidity. Interest rate movements and refinancing costs will influence future FFO growth, while the recently declared monthly dividend of $0.10167 per share (an annualized $1.22) underscores management's commitment to shareholder distributions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations